News | Radiopharmaceuticals and Tracers | November 13, 2018

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

Iodine-131 is critical radioisotope for diagnoses and treatment of thyroid cancer and hyperthyroidism

University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

November 13, 2018 — The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a radioisotope widely used for diagnosing and treating thyroid cancer and hyperthyroidism. The shipment makes MURR the only supplier of I-131 in the United States and the first U.S. supplier since the 1980s.

According to the American Cancer Society, thyroid cancer is “the most rapidly increasing cancer in the U.S.,”1 with diagnoses tripling in the last three decades. There will be an estimated 53,990 new cases of thyroid cancer in the U.S. in 2018 with an estimated 2,060 deaths from the disease, according to the National Cancer Institute. A domestic supply of I-131 is vital due to increasing demand and the isotope’s short shelf-life, according to MURR.

“Supplying I‑131 is part of a strategic initiative by the University of Missouri and MURR to address medical isotope shortages and further the University’s research mission,” said David Robertson, executive director of MURR.

I-131 sodium iodide became the first U.S. Food and Drug Administration (FDA)-approved radiopharmaceutical in 1951 and is one of the most widely used radiopharmaceuticals in the United States. The isotope’s unique properties enable both diagnostic imaging and treatment of cancer and hyperthyroidism. Since the thyroid gland naturally absorbs iodine, I‑131 can be targeted directly to thyroid tumors to remove cancerous tissue and treat the disease.

With only an eight-day half-life, stockpiling I-131 is impossible and logistics are complicated, making a reliable supplier critical for patients. MURR is one of only a handful of research reactors around the world that supply I-131 to drug manufacturers who, in turn, supply radiopharmaceuticals for distribution to hospitals and patients.

I-131 joins a growing lineup of isotope active ingredients supplied by MURR for radiopharmaceuticals including Therasphere, Quadramet and Lutathera, which was recently approved by the FDA to treat pancreatic cancer.

For more information: www.murr.missouri.edu

Reference

1. Key Statistics for Thyroid Cancer. Retrieved from https://www.cancer.org/cancer/thyroid-cancer/about/key-statistics.html

 

Related Content

iCAD's ProFound AI Wins Best New Radiology Solution in 2019 MedTech Breakthrough Awards
News | Computer-Aided Detection Software | September 09, 2019
iCAD Inc. announced MedTech Breakthrough, an independent organization that recognizes the top companies and solutions...
Imaging Biometrics and Medical College of Wisconsin Awarded NIH Grant
News | Neuro Imaging | September 09, 2019
Imaging Biometrics LLC (IB), in collaboration with the Medical College of Wisconsin (MCW), has received a $2.75 million...
ASNC Announces Multisocietal Cardiac Amyloidosis Imaging Consensus
News | Cardiac Imaging | September 09, 2019
September 9, 2019 — The American Society of Nuclear Cardiology (ASNC) published a new expert consensus document along
A 3-D printed tungsten pre-clinical X-ray system collimator. 3D printed, additive manufacturing for medical imaging.

A 3-D printed tungsten pre-clinical X-ray system collimator. The tungsten alloy powder is printed into the form desired and is laser fused so it can be machined and finished. Previously, making collimators from Tungsten was labor intensive because it required working with sheets of the metal to create the collimator matrix. 

Feature | Medical 3-D Printing | September 04, 2019 | By Steve Jeffery
In ...
New Radiomics Model Uses Immunohistochemistry to Predict Thyroid Nodules

Workflow of radiomics analysis for IHC indicators. Yellow lines denote area of analysis; red lines denote ROI for radiomic features extraction. X = original image, L = low-pass filter, H = high-pass filter. Image courtesy of Jiabing Gu, et al.

News | Artificial Intelligence | September 03, 2019
Researchers have validated a first-of-its-kind machine learning–based model to evaluate immunohistochemical (IHC)...
A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one hold out who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

A SPECT nuclear scan of the heart to show perfusion defects in the myocardium due to coronary artery blockages or heart attack. The imaging uses the Mo-99 based medical imaging isotope Tc-99m. The U.S. government has created policy to move away from use of highly enriched uranium (HEU) to low-enriched uranium (LEU) for Mo-99 isotope production, but there is one holdout who has not yet converted before a 2020 deadline. Photo courtesy of Philips Healthcare.

Feature | Nuclear Imaging | August 30, 2019 | Dave Fornell, Editor
In a surprising move, the National Institute for Radioelements (IRE) has applied for a new license to export highly e
University of Alabama at Birmingham Leading Production of Theranostic Radioisotope

Image courtesy of the University of Alabama at Birmingham

News | Radiopharmaceuticals and Tracers | August 29, 2019
The University of Alabama at Birmingham, in conjunction with researchers at the University of Wisconsin and Argonne...
FDA Encourages Inclusion of Male Patients in Breast Cancer Clinical Trials
News | Women's Health | August 26, 2019
The U.S. Food and Drug Administration (FDA) released a new draft guidance that encourages including male patients in...
Improved Imaging Technique Could Increase Chances of Prostate Cancer Survival
News | Prostate Cancer | August 20, 2019
According to the American Cancer Society, approximately one in nine men will be diagnosed with prostate cancer in their...
United Imaging Announces First U.S. Clinical Installation of uExplorer Total-body PET/CT
News | PET-CT | August 15, 2019
United Imaging announced that its uExplorer total-body positron emission tomography/computed tomography (PET/CT) system...